Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone. Hope you’re powering through this short week before the holiday and aren’t too distracted by daydreams of your Thanksgiving dessert of choice. This is Rachel Cohrs sitting in today. Our morning cup of stimulation comes in the form of a matcha latte. Here are a few items to help you catch up this Tuesday, and as always, stay in touch. …

Safety concerns are growing over Biogen’s (BIIB) Alzheimer’s drug Aduhelm as a new paper showed brain swelling in 35% of clinical trial patients, Bloomberg tells us. Most people did not experience symptoms, however. The study in JAMA Neurology is one of the first formal publications of data from the company’s final-stage trials of Aduhelm.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment